The Federation of Infection Societies Conference offers sponsors the perfect opportunity to interact with a large cross-section of key stakeholders at the UKs largest annual infection event.
We have bespoke sponsorship packages available which can be tailored to any organisation size and requirements.
Packages can include:
Please contact Pharmatologists on +44 (0) 1223 903320 and ask to speak to a member of the exhibitions team.
Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer.
Today, Pfizer UK offers patients access to a diverse portfolio of over 20 antibacterial and
More than ever, the world needs new approaches to preventing and fighting infections.
Pfizer joined with over 100 industry partners to sign the Declaration on Combating Antimicrobial Resistance, announced in January 2016 at Davos, to call on governments to join industry in taking swift, coordinated action.
Pfizer sponsors the most comprehensive global antimicrobial resistance surveillance program in the industry. These programmes provide critical data regarding antibiotic resistance patterns that enable physicians and healthcare providers to make the most appropriate treatment choices for their patients. The goals of these programmes are to provide important information on resistance and to assess antibiotic stewardship.
Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of channels, including medical symposia, to ensure appropriate utilisation of antibiotics and improve infection prevention and control.
Pfizer is proud to sponsor the FIS 2017 Congress and we look forward to sharing this meeting
Date of preparation: November 2017
The TARGET (Treat Antibiotics Responsibly: Guidance, Education, Tools) toolkit comprises a series of FREE resources that can each be used to support prescribers’ and patients’ responsible antibiotic use. The toolkit is designed to be used by the whole primary care team within the GP practice or out of hours setting. These resources can be used flexibly, either as standalone materials or as part of an integrated package. Using the TARGET Antibiotics Toolkit resources will enable primary care organisations to demonstrate compliance with the Health and Social Care Act 2008: Code of Practice on the prevention and control of infections and related guidance. Visit the TARGET stand to view the range of resources available and take part in our research survey to be entered into a draw to win one of 5 sets of Christmas microbes! Visit our website http://www.rcgp.org.uk/TARGETantibiotics/ or follow us on Twitter @TARGETabx
ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to delivering effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For further information, visit www.viivhealthcare.com.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.
Oxford University Press is proud to publish the Journal of Antimicrobial Chemotherapy; visit our stand at FIS to find out more about the Journal and to pick up a complimentary print copy. Journal of Antimicrobial Chemotherapy is the official journal of the British Society for Antimicrobial Chemotherapy (BSAC) and is among the foremost international journals in antimicrobial research. Published monthly, the high Impact Factor (5.071) Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents.
Oxford University Press’ worldwide publishing furthers the University's objectives of excellence in scholarship, research, and education.
The Public Health England (PHE) National Infections Service (NIS) consists of eight clinical and three food, water, and environmental testing laboratories operating across England, linked to centres of excellence at Colindale (London) and Porton (Wiltshire). Collectively, they provide a range of clinical, reference, and public health microbiology tests and services to the UK NHS and allied healthcare partners. Our leadership in communicable diseases, field epidemiology and rapid investigations is supported by real-time data collection and analysis, and emergency preparedness planning and response activities. We are a WHO Collaborating Centre on Mass Gatherings and our legacy from London 2012 includes improved surveillance systems, rapid laboratory testing, and the analysis of public health implications. NIS also provides collaborative contract research services to industry and academia, with a specific focus on the evaluation and development of novel antimicrobials, vaccines, and in vitro diagnostics. For more information on any of the above please contact Alan Weddell, Senior Business Development Manager (NIS Laboratories) on +44 (0) 782 534 2796 or e-mail email@example.com
Insmed is a global, biopharmaceutical company whose mission is to transform the lives of patients with serious, rare diseases
Momentum Bioscience was founded to develop rapid tests for critically-important clinical specimens within the hospital microbiology laboratory, is headquartered near Cardiff and has a R&D facility near Oxford in the UK.
Momentum is developing a range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections. Up to 90% of patients suspected of sepsis are administered IV antibiotics and are confirmed negative for a bloodstream infection at 5-days. Momentum’s core ETGA® technology allows universal detection of viable organisms which can allow the early reporting of negative blood cultures, from patients suspected of sepsis, on day 1 instead of day 5 with an NPV of 99.5%. Thus reducing the over use of unnecessary antimicrobials.
Today, there is no other technology except Momentum’s for confidently and rapidly reporting negative cultures.
To find out more, please visit www.momentumbio.co.uk
ICNet is a clinical surveillance software suite that aggregates data from existing clinical information systems to create an integrated platform, monitoring relevant data and correlating patients’ specific conditions & treatments. Customised alerts provide timely, actionable information. Sophisticated data analysis tools create reports and automates mandatory data submission. ICNet Pharmacy monitors medications, providing antimicrobial stewardship, anti-coagulation therapy monitoring, outbreak management & ADE reports, for better allergy alarms, infection prevention, cost analysis and enhanced patient safety. ICNet is a wholly owned subsidiary of Baxter Healthcare.
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. GenMark’s ePlex®: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.
For the first time at the FIS congress Mobidiag will be exhibiting at stand 27. Discover high- and low-volume automated diagnostic solutions for infectious diseases based on hi-plex real-time PCR technology.
Amplidiag® assays allow rapid and reliable detection of enteric and antibiotic resistance markers, complemented by the Amplidiag® Easy platform allowing workflow automation from sample to results.
Mobidiag will also be introducing its new cartridge-based Novodiag® instrument for fully automated on-demand targeted and syndromic testing - a game-changer for the microbiology laboratory. Visit our stand to discover the complete Novodiag solution and learn more about our upcoming assays.
At Biocomposites, we are distinct in that our team of specialists is singularly focused on the development of innovative calcium compounds for surgical use.
With over 25 years’ experience and an unrivalled dedication to quality, the products we research, engineer and manufacture are at the forefront of calcium technology. Our innovative products range from bone grafts to matrices that elute supra-MIC levels of antibiotics at the site of infection.
We are proud to be driving improved outcomes across a wide range of clinical applications, in musculoskeletal infection, trauma, spine and sports injuries, for surgeons and patients alike.
Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
Nordic Pharma UK is a specialty pharmaceutical company focusing on essential and hard to obtain medicines that are often outside of the scope of larger companies. We pride ourselves on responding to needs in the NHS by providing healthcare professionals with products that make a real clinical difference for their patients. We bring products to market that meet clear needs and we will continue to work with microbiologists and their clinical colleagues at a time when antibiotic resistance is a significant issue.
Curetis’ Unyvero multiplex PCR system is an automated, fast and comprehensive diagnostic tool. We focus on severe infections in hospitalized patients, such as implant and tissue infections, pneumonia, and bloodstream infections. Curetis offers now also a new application for intra-abdominal infections, with rapid detection of relevant pathogens, resistance markers and toxins from various sample types (e.g. aspirates, tissue, and ascites in positive flagged blood cultures).
It allows antibiotic diagnostics and therapy in a targeted and rapid manner. It is a simple and deployable technology that yields results in less than 5 hours.
ETS is the European Tissue Paper Industry Association. Its members represent the majority of tissue paper producers throughout Europe and around 90% of the total European tissue production. Spreading the message of optimal hand drying after hand washing as a factor to stay healthy and hygienic, is among ETS key priorities. ETS stays updated with the relevant market and technology developments while keeping up with the latest environmental and product safety regulatory requirements. ETS was founded in 1971 and is based in Brussels. For more information www.europeantissue.com.
Pathology Group is a provider of locum and permanent pathologists to the NHS, with extensive opportunities across the UK through our exclusive supplier agreements with national and regional Trusts.
To our clients, we provide a personal service and offer full support through the entire recruitment process. Our aim is to build the highest quality flexible workforce possible, bridging your resourcing gaps by filling rotas and ensuring that there is always a pathologist to meet every one of your patient’s needs.
To our candidates, our specialist consultants will support you with expert advice, whilst placing you within a desirable working environment. When you register with us you’ll gain a career partner, committed to helping you develop and progress in your specialism.
Please join us at the FIS conference, our Sales Manager, Nicola Humroy who heads up the microbiology division would be delighted to meet with you.
Hospitals are increasingly encountering unpredictable resistance patterns clinically whilst being faced with the need to minimise broad-spectrum antibiotic use to prevent and reduce antimicrobial resistance. For patients with sepsis, time to effective and optimised therapy is critical.
Accelerate Diagnostics is an in-vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and Healthcare Associated Infections. The company's fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture kit, Accelerate PhenoTest™ BC, utilise proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to definitive, actionable antimicrobial susceptibility and MIC results by 1 to 2 days, compared with conventional methods
Rapid ID/AST diagnostics with the Accelerate PhenoTM System allow institutions to:
• Escalate to effective therapy sooner
• Optimise and de-escalate therapy earlier
• Improve patient outcomes and reduce healthcare costs
• Support your antimicrobial stewardship efforts
• Reduce antibiotic resistance
• Decrease C. difficile risk
Cardiome’s mission is to offer patients and healthcare providers innovative therapeutic options that effectively, safely and conveniently manage acute medical conditions to improve health and quality of life
Cardiome has two marketed, in-hospital, cardiology products: BRINAVESS® (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets, and co-promotes EXEMBOL® (argatroban monohydrate), an anticoagulant indicated for use in patients with heparin induced thrombocytopenia (HIT) type II, with Mitsubishi Tanabe Pharma Europe in the UK.
Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension (PAH) for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.
As a pharmaceutical company, Eumedica ensures the continuity of access to quality & lifesaving therapeutic solutions for healthcare practitioners and patients. We focus on developing and maintaining a diversified range of therapeutic solutions that cover critical unmet medical needs.
The therapeutic areas we focus on are: Infectious Diseases; Cardiovascular Disorders & Hematology; Gastroenterology and Gastro Intestinal Surgery; Central Nervous System – Psychosis management; Anesthesiology.